CAR-T Therapy for Multiple Myeloma: New Second-Line Treatment Approvals

Italy has approved the use of the CAR-T cell therapy cilta-cel as a second-line treatment for patients diagnosed with multiple myeloma. This regulatory and reimbursement shift allows the therapy to be administered earlier in the clinical pathway, providing an option for patients who have not responded to initial treatment lines.

The expansion of cilta-cel’s application represents a move toward utilizing advanced cellular therapies sooner in the treatment process. According to reporting from Quotidiano Sanità and Corriere della Sera, the therapy is now reimbursed, which facilitates broader patient access to this specific medical intervention.

Understanding CAR-T Therapy

Chimeric antigen receptor (CAR) T-cell therapy is an innovative approach to treating certain cancers, including multiple myeloma. The process involves collecting a patient’s own T-cells—a type of immune cell—and genetically modifying them in a laboratory to recognize and attack specific proteins on the surface of cancer cells.

Once these modified cells are reintroduced into the patient’s bloodstream, they act as a targeted defense system designed to identify and destroy the myeloma cells more effectively than traditional therapies.

Clinical Implementation in Italy

The rollout of these advanced treatments is occurring across specialized centers in Italy. The GOM (Centro di Oncologia Medica) in Reggio Calabria has been identified as one of the first centers in the country to implement these new cures.

As reported by RaiNews and ildispaccio.it, the center is operating at the frontier of CAR-T therapy, integrating these complex treatments into the regional healthcare infrastructure to treat multiple myeloma.

Emerging Research and In Vivo Approaches

While current CAR-T therapies like cilta-cel require cells to be extracted and modified outside the body, new research is exploring the possibility of in vivo CAR-T therapy.

The Osservatorio Terapie Avanzate has noted the emergence of early data regarding the safety and efficacy of these in vivo methods. In vivo therapy aims to modify the T-cells directly inside the patient’s body, which would potentially simplify the treatment process by eliminating the need for external laboratory modification and re-infusion.

This research represents a potential next step in the evolution of hematological oncology, moving toward more streamlined ways of delivering genetically modified immune responses to fight cancer.